Quick Answer
Protagonist Therapeutics, Inc reported Cash and Equivalents of $128.39 million for fiscal year 2025.
Protagonist Therapeutics, Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $128.39M | +32.0% |
| 2024 | $97.25M | -47.9% |
| 2023 | $186.73M | +48.5% |
| 2022 | $125.74M | +1.7% |
| 2021 | $123.67M | +5.4% |
| 2020 | $117.36M | +255.6% |
| 2019 | $33.01M | -59.9% |
| 2018 | $82.23M | -22.4% |
| 2017 | $106.03M | +402.9% |
| 2016 | $21.08M | +420.0% |
| 2015 | $4.05M | -56.5% |
| 2014 | $9.32M | +10.2% |
| 2013 | $8.46M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $113.71M | -13.3% | -32.5% |
| June 30, 2025 | $168.54M | -52.6% | +20.7% |
| March 31, 2025 | $139.65M | -19.1% | +43.6% |
| December 31, 2024 | $97.25M | -47.9% | -25.8% |
| September 30, 2024 | $131.12M | -43.1% | -63.1% |
| June 30, 2024 | $355.64M | +51.1% | +106.1% |
| March 31, 2024 | $172.57M | +35.2% | -7.6% |
| December 31, 2023 | $186.73M | +48.5% | -19.0% |
- Protagonist Therapeutics, Inc showed an increase of +32.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Protagonist Therapeutics, Inc’s cash and equivalents has grown by 1417.6% (from $8.46 million to $128.39 million).
- The most recent figure is from Protagonist Therapeutics, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: